Cytospire Therapeutics names Sumeet Ambarkhane chief medical officer

• Cytospire Therapeutics named Sumeet Ambarkhane as chief medical officer, strengthening leadership ahead of CYT X300 first-in-human studies.
• Ambarkhane was chief medical officer at Pathios Therapeutics, leading clinical development strategy for its immuno-oncology pipeline.
• He previously served as chief medical officer at Alligator Bioscience, supporting mitazalimab’s progression toward Phase 3 development in pancreatic cancer.
• Earlier roles included senior global program medical director at MorphoSys, advancing tafasitamab through approvals, plus development posts at UCB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeArc Ventures published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.